microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts

Journal of Nuclear Medicine

Volumn 45, Issue 8, 2004, Pages 1390-1397

  Chen, Xiaoyuan ^a   Park, Ryan ^a   Hou, Yingping ^a   Tohme, Michel ^a   Shahinian, Antranik H ^a   Bading, James R ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

64Cu; Bombesin; Gastrin releasing peptide receptor; microPET; Prostate cancer

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID[3 LYSINE]BOMBESIN; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID[3 LYSINE]BOMBESIN CU 64; BOMBESIN[3 LYSINE]; BOMBESIN[4 TYROSINE] I 125; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BOMBESIN; BOMBESIN RECEPTOR; CU DOTA (LYS3)BOMBESIN; CU-DOTA-(LYS3)BOMBESIN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ORGANOMETALLIC COMPOUND; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CANCER CELL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; RECEPTOR BINDING; TEMPERATURE DEPENDENCE; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; WHOLE BODY AUTORADIOGRAPHY; ADENOCARCINOMA; ANIMAL; ANTIBODY SPECIFICITY; AUTORADIOGRAPHY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION; INSTRUMENTATION; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; AUTORADIOGRAPHY; BOMBESIN; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 4544291850     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 18F-labeled deoxyglucose. J Urol. 1996;155:994-998.
2. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 2001;57:108-111.
3. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990-995.
4. Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27:1415-1419.
5. 18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168:273-280.
6. 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805-1814.
7. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61:110-117.
8. 18F- fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43:187-199.
9. Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1380-1384.
10. 11C] acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1492-1495.
11. 11C-Acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181-186.
12. 11C-Acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44:549-555.
13. Bonasera TA, O'Neil JP, Xu M, et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med. 1996;37:1009-1015.
14. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
15. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate. 2000;42:295-303.
16. 4) bombesin by tumor cells. Prostate. 1994;25:29-38.
17. Jongsma J, Oomen MH, Noordzij MA, et al. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate. 2000;42:34-44.
18. Szepeshazi K, Halmos G, Schally AV, et al. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. J Cancer Res Clin Oncol. 1999;125:444-452.
19. Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z. Peptide analogs in the therapy of prostate cancer. Prostate. 2000;45:158-166.
20. 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001;42:1722-1727.
21. Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694-1699.
22. Baidoo KE, Lin KS, Zhan Y, Finley P, Scheffel U, Wagner HN Jr. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem. 1998;9:218-225.
23. 99mTc-Labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine- based bifunctional chelating agent. Bioconjug Chem. 1999;10:254-260.
24. 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl Med Biol. 2002;29:553-560.
25. 99mTc(I)- postlabeled high affinity bombesin analogue as a potential tumor imaging agent. Bioconjug Chem. 2002;13:599-604.
26. Wu AM, Yazaki PJ, Tsai S, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA. 2000;97:8495-8500.
27. 64Cu-labeled bombesin analogue. Bioconjug Chem. 2003;14:756-763.
28. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991;12:450-482.
29. Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001;28:1421-1429.
30. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331:1116-1121.
31. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/ gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998;25:424-430.
32. 18F-Labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179-189.
33. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
34. Smith CJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol. 2003;30:861-868.
35. 111In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med. 2002;43:1650-1656.
36. 4]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer. 1999;83:657-663.
37. 111In- labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med. 2003;44:823-831.
38. 2: an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem. 2003;14:93-102.
39. Slice LW, Yee HF Jr, Walsh JH. Visualization of internalization and recycling of the gastrin releasing peptide receptor-green fluorescent protein chimera expressed in epithelial cells. Recept Channels. 1998;6:201-212.
40. Grady EF, Slice LW, Brant WO, Walsh JH, Payan DG, Bunnett NW. Direct observation of endocytosis of gastrin releasing peptide and its receptor. J Biol Chem. 1995;270:4603-4611.